Molecular genetics of familial hematuric diseases

Nephrology Dialysis Transplantation

Volumn 28, Issue 12, 2013, Pages 2946-2960

  Deltas, Constantinos ^a   Pierides, Alkis ^a,b   Voskarides, Konstantinos ^a  

^a UNIVERSITY OF CYPRUS   (Cyprus)

^b Hippocrateon Hospital   (Cyprus)

Author keywords

Alport TBMN CFHR5 C3GN GFND; COL4 CFHR5 FN1; Familial microscopic hematuria; Genetic and phenotypic heterogeneity; Genetic modifiers

Indexed keywords

COLLAGEN TYPE 4; COMPLEMENT FACTOR H; FIBRONECTIN; PROTEIN COMPLEMENT FACTOR H RELATED 5; UNCLASSIFIED DRUG;

ALPORT SYNDROME; C3 GLOMERULONEPHRITIS; CFHR5 GENE; CHROMOSOME MAP; COL4A1 GENE; COL4A3 GENE; COL4A4 GENE; COL5A5 GENE; END STAGE RENAL DISEASE; FAMILIAL DISEASE; FAMILIAL HEMATURIC DISEASE; FAMILIAL MICROSCOPIC HEMATURIA; FN1 GENE; GENE MUTATION; GENETIC ANALYSIS; GENETIC VARIABILITY; GLOMERULAR FILTRATION BARRIER; GLOMERULONEPHRITIS; GLOMERULOPATHY; GLOMERULOPATHY WITH FIBRONECTIN DEPOSITS; HEMATURIA; HISTOLOGY; HUMAN; IMMUNOREACTIVITY; KIDNEY DISEASE; MISSENSE MUTATION; MODIFIER GENE; MOLECULAR GENETICS; NONHUMAN; PHENOTYPIC VARIATION; PRIORITY JOURNAL; PROTEINURIA; REVIEW; THIN BASEMENT MEMBRANE NEPHROPATHY; X CHROMOSOME RECESSIVE INHERITANCE;

ALPORT-TBMN-CFHR5/C3GN-GFND; COL4-CFHR5-FN1; FAMILIAL MICROSCOPIC HEMATURIA; GENETIC AND PHENOTYPIC HETEROGENEITY; GENETIC MODIFIERS;

BIOLOGICAL MARKERS; COLLAGEN TYPE IV; COMPLEMENT SYSTEM PROTEINS; FIBRONECTINS; HEMATURIA; HUMANS; MOLECULAR BIOLOGY; MUTATION;

EID: 84890039318     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gft253     Document Type: Review

References (104)

1. Spetie DN, Nadasdy T, Nadasdy G et al. Proposed pathogenesis of idiopathic loin pain-hematuria syndrome. Am J Kidney Dis 2006; 47: 419-427.
2. Smith HS, Bajwa ZH. Loin pain hematuria syndrome-visceral or neuropathic pain syndrome? Clin J Pain 2012; 28: 646-651.
3. Heath KE, Campos-Barros A, Toren A et al. Nonmuscle myosin heavy chain IIA mutations define a spectrum of autosomal dominant macrothrombocytopenias: May-Hegglin anomaly and Fechtner, Sebastian, Epstein, and Alport-like syndromes. Am J Hum Genet 2001; 69: 1033-1045.
4. Seri M, Pecci A, Di Bari F et al. MYH9-related disease: May-Hegglin anomaly, Sebastian syndrome, Fechtner syndrome, and Epstein syndrome are not distinct entities but represent a variable expression of a single illness. Medicine (Baltimore) 2003; 82: 203-215.
5. Strom EH, Banfi G, Krapf R et al. Glomerulopathy associated with predominant fibronectin deposits: a newly recognized hereditary disease. Kidney Int 1995; 48: 163-170.
6. Castelletti F, Donadelli R, Banterla F et al. Mutations in FN1 cause glomerulopathy with fibronectin deposits. Proc Natl Acad Sci USA 2008; 105: 2538-2543.
7. Kadler KE, Baldock C, Bella J et al. Collagens at a glance. J Cell Sci 2007; 120(Pt 12): 1955-1958.
8. Tsiakkis D, Pieri M, Koupepidou P et al. Genotype-phenotype correlation in X-linked Alport syndrome patients carrying missense mutations in the collagenous domain of COL4A5. Clin Genet 2012; 82: 297-299.
9. Miner JH. Glomerular basement membrane composition and the filtration barrier. Pediatr Nephrol 2011; 26: 1413-1417.
10. Alport AC. Hereditary familial congenital haemorrhagic nephritis. Br Med J 1927; 1: 504-506.
11. Jefferson JA, Lemmink HH, Hughes AE et al. Autosomal dominant Alport syndrome linked to the type IV collage alpha 3 and alpha 4 genes (COL4A3 and COL4A4). Nephrol Dial Transplant 1997; 12: 1595-1599.
12. Marcocci E, Uliana V, Bruttini M et al. Autosomal dominant Alport syndrome: molecular analysis of the COL4A4 gene and clinical outcome. Nephrol Dial Transplant 2009; 24: 1464-1471.
13. Pescucci C, Mari F, Longo I et al. Autosomal-dominant Alport syndrome: natural history of a disease due to COL4A3 or COL4A4 gene. Kidney Int 2004; 65: 1598-1603.
14. Longo I, Porcedda P, Mari F et al. COL4A3/COL4A4 Mutations: from familial hematuria to autosomal-dominant or recessive Alport syndrome. Kidney Int 2002; 61: 1947-1956.
15. Savige J, Gregory M, Gross O et al. Expert guidelines for the management of Alport syndrome and thin basement membrane nephropathy. J Am Soc Nephrol 2013; 24: 364-375.
16. Levy M, Feingold J. Estimating prevalence in single-gene kidney diseases progressing to renal failure. Kidney Int 2000; 58: 925-943.
17. Kashtan CE. Alport syndrome. An inherited disorder of renal, ocular, and cochlear basement membranes. Medicine (Baltimore) 1999; 78: 338-360.
18. Pajari H, Kaariainen H, Muhonen T et al. Alport's syndrome in 78 patients: epidemiological and clinical study. Acta Paediatr 1996; 85: 1300-1306.
19. Jais JP, Knebelmann B, Giatras I et al. X-linked Alport syndrome: natural history and genotype-phenotype correlations in girls and women belonging to 195 families: a 'European Community Alport Syndrome Concerted Action' study. J Am Soc Nephrol 2003; 14: 2603-2610.
20. Kashtan CE. Women with Alport syndrome: risks and rewards of kidney donation. Nephrol Dial Transplant 2009; 24: 1369-1370.
21. Rheault MN, Kren SM, Hartich LA et al. X-inactivation modifies disease severity in female carriers of murine X-linked Alport syndrome. Nephrol Dial Transplant 2010; 25: 764-769.
22. Liapis H, Gaut JP. The renal biopsy in the genomic era. Pediatr Nephrol 2012. [Epub ahead of print].
23. Haas M. Alport syndrome and thin glomerular basement membrane nephropathy: a practical approach to diagnosis. Arch Pathol Lab Med 2009; 133: 224-232.
24. Kashtan CE. Familial hematurias: what we know and what we don't. Pediatr Nephrol 2005; 20: 1027-1035.
25. Liapis H, Foster K, Theodoropoulou E et al. Phenotype/genotype correlations in the ultrastructure of monogenetic glomerular diseases. Ultrastruct Pathol 2004; 28: 181-197.
26. Artuso R, Fallerini C, Dosa L et al. Advances in Alport syndrome diagnosis using next-generation sequencing. Eur J Hum Genet 2012; 20: 50-57.
27. Nakanishi K, Yoshikawa N, Iijima K et al. Immunohistochemical study of alpha 1-5 chains of type IV collagen in hereditary nephritis. Kidney Int 1994; 46: 1413-1421.
28. Heidet L, Cai Y, Guicharnaud L et al. Glomerular expression of type IV collagen chains in normal and X-linked Alport syndrome kidneys. Am J Pathol 2000; 156: 1901-1910.
29. Massella L, Gangemi C, Giannakakis K et al. Prognostic value of glomerular collagen IV immunofluorescence studies in male patients with X-linked Alport Syndrome. Clin J Am Soc Nephrol 2013; 8: 749-755.
30. Gross O, Netzer KO, Lambrecht R et al. Meta-analysis of genotype-phenotype correlation in X-linked Alport syndrome: impact on clinical counselling. Nephrol Dial Transplant 2002; 17: 1218-1227.
31. Jais JP, Knebelmann B, Giatras I et al. X-linked Alport syndrome: natural history in 195 families and genotype-phenotype correlations in males. J Am Soc Nephrol 2000; 11: 649-657.
32. Kobayashi T, Uchiyama M. Characterization of assembly of recombinant type IV collagen alpha3, alpha4, and alpha5 chains in transfected cell strains. Kidney Int 2003; 64: 1986-1996.
33. Bekheirnia MR, Reed B, Gregory MC et al. Genotype-phenotype correlation in X-linked Alport syndrome. J Am Soc Nephrol 2010; 21: 876-883.
34. Slajpah M, Gorinsek B, Berginc G et al. Sixteen novel mutations identified in COL4A3, COL4A4, and COL4A5 genes in slovenian families with Alport syndrome and benign familial hematuria. Kidney Int 2007; 71: 1287-1295.
35. Wei G, Zhihong L, Huiping C et al. Spectrum of clinical features and type IV collagen alpha-chain distribution in chinese patients with Alport syndrome. Nephrol Dial Transplant 2006; 21: 3146-3154.
36. Becknell B, Zender GA, Houston R et al. Novel X-linked glomerulopathy is associated with a COL4A5 missense mutation in a non-collagenous interruption. Kidney Int 2011; 79: 120-127.
37. Demosthenous P, Voskarides K, Stylianou K et al. X-linked Alport syndrome in hellenic families: phenotypic heterogeneity and mutations near interruptions of the collagen domain in COL4A5. Clin Genet 2012; 81: 240-248.
38. Wilson JC, Yoon HS, Walker RJ et al. A novel Cys1638Tyr NC1 domain substitution in alpha5(IV) collagen causes Alport syndrome with late onset renal failure without hearing loss or eye abnormalities. Nephrol Dial Transplant 2007; 22: 1338-1346.
39. Dagher H, Buzza M, Colville D et al. A comparison of the clinical, histopathologic, and ultrastructural phenotypes in carriers of X-linked and autosomal recessive Alport's syndrome. Am J Kidney Dis 2001; 38: 1217-1228.
40. Heidet L, Arrondel C, Forestier L et al. Structure of the human type IV collagen gene COL4A3 and mutations in autosomal Alport syndrome. J Am Soc Nephrol 2001; 12: 97-106.
41. Zhang Y, Wang F, Ding J et al. Genotype-phenotype correlations in 17 Chinese patients with autosomal recessive Alport syndrome. Am J Med Genet A 2012; 158A: 2188-2193.
42. Pont-Kingdon G, Sumner K, Gedge F et al. Molecular testing for adult type Alport syndrome. BMC Nephrol 2009; 10: 38.
43. Barker DF, Atkin CL, Gregory MC et al. Application of linked markers for genetic diagnosis of Alport syndrome. Contrib Nephrol 1996; 117: 29-45.
44. Martin P, Heiskari N, Zhou J et al. High mutation detection rate in the COL4A5 collagen gene in suspected Alport syndrome using PCR and direct DNA sequencing. J Am Soc Nephrol 1998; 9: 2291-2301.
45. Barker DF, Denison JC, Atkin CL et al. Common ancestry of three Ashkenazi-American families with Alport syndrome and COL4A5 R1677Q. Hum Genet 1997; 99: 681-684.
46. Barker DF, Denison JC, Atkin CL et al. Efficient detection of Alport syndrome COL4A5 mutations with multiplex genomic PCR-SSCP. Am J Med Genet 2001; 98: 148-160.
47. Pierides A, Voskarides K, Athanasiou Y et al. Clinico-pathological correlations in 127 patients in 11 large pedigrees, segregating one of three heterozygous mutations in the COL4A3/ COL4A4 genes associated with familial haematuria and significant late progression to proteinuria and chronic kidney disease from focal segmental glomerulosclerosis. Nephrol Dial Transplant 2009; 24: 2721-2729.
48. Temme J, Peters F, Lange K et al. Incidence of renal failure and nephroprotection by RAAS inhibition in heterozygous carriers of X-chromosomal and autosomal recessive Alport mutations. Kidney Int 2012; 81: 779-783.
49. Voskarides K, Damianou L, Neocleous V et al. COL4A3/ COL4A4 Mutations producing focal segmental glomerulosclerosis and renal failure in thin basement membrane nephropathy. J Am Soc Nephrol 2007; 18: 3004-3016.
50. Deltas C, Pierides A, Voskarides K. The role of molecular genetics in diagnosing familial hematuria(s). Pediatr Nephrol 2012; 27: 1221-1231.
51. Thiagarajan G, Li Y, Mohs A et al. Common interruptions in the repeating tripeptide sequence of non-fibrillar collagens: sequence analysis and structural studies on triple-helix peptide models. J Mol Biol 2008; 376: 736-748.
52. Andrews KL, Mudd JL, Li C et al. Quantitative trait loci influence renal disease progression in a mouse model of Alport syndrome. Am J Pathol 2002; 160: 721-730.
53. Bihoreau MT, Megel N, Brown JH et al. Characterization of a major modifier locus for polycystic kidney disease (Modpkdr1) in the Han:SPRD(cy/+) rat in a region conserved with a mouse modifier locus for Alport syndrome. Hum Mol Genet 2002; 11: 2165-2173.
54. Kang JS, Wang XP, Miner JH et al. Loss of alpha3/alpha4(IV) collagen from the glomerular basement membrane induces a strain-dependent isoform switch to alpha5alpha6(IV) collagen associated with longer renal survival in Col4a3-/- Alport mice. J Am Soc Nephrol 2006; 17: 1962-1969.
55. Piccini M, Casari G, Zhou J et al. Evidence for genetic heterogeneity in benign familial hematuria. Am J Nephrol 1999; 19: 464-467.
56. Rogers PW, Kurtzman NA, Bunn SM, Jr, et al. Familial benign essential hematuria. Arch Intern Med 1973; 131: 257-262.
57. Nieuwhof CM, de Heer F, de Leeuw P et al. Thin GBM nephropathy: premature glomerular obsolescence is associated with hypertension and late onset renal failure. Kidney Int 1997; 51: 1596-1601.
58. Nogueira M, Cartwright J, Jr, Horn K et al. Thin basement membrane disease with heavy proteinuria or nephrotic syndrome at presentation. Am J Kidney Dis 2000; 35: E15.
59. van Paassen P, van Breda Vriesman PJ, van Rie H et al. Signs and symptoms of thin basement membrane nephropathy: a prospective regional study on primary glomerular disease-the Limburg Renal Registry. Kidney Int 2004; 66: 909-913.
60. Norby SM, Cosio FG. Thin basement membrane nephropathy associated with other glomerular diseases. Semin Nephrol 2005; 25: 176-179.
61. Haas M. Thin glomerular basement membrane nephropathy: incidence in 3471 consecutive renal biopsies examined by electron microscopy. Arch Pathol Lab Med 2006; 130: 699-706.
62. Voskarides K, Patsias C, Pierides A et al. COL4A3 Founder mutations in Greek-Cypriot families with thin basement membrane nephropathy and focal segmental glomerulosclerosis dating from around 18th century. Genet Test 2008; 12: 273-278.
63. Hoefele J, Lange-Sperandio B, Ruessmann D et al. Novel heterozygous COL4A3 mutation in a family with late-onset ESRD. Pediatr Nephrol 2010; 25: 1539-1542.
64. Tonna S, Wang YY, MacGregor D et al. The risks of thin basement membrane nephropathy. Semin Nephrol 2005; 25: 171-175.
65. Frasca GM, Onetti-Muda A, Mari F et al. Thin glomerular basement membrane disease: clinical significance of a morphological diagnosis-a collaborative study of the Italian Renal Immunopathology Group. Nephrol Dial Transplant 2005; 20: 545-551.
66. Tsukaguchi H, Sudhakar A, Le TC et al. NPHS2 Mutations in late-onset focal segmental glomerulosclerosis: R229Q is a common disease-associated allele. J Clin Invest 2002; 110: 1659-1666.
67. Tonna S, Wang YY, Wilson D et al. The R229Q mutation in NPHS2 may predispose to proteinuria in thin-basement-membrane nephropathy. Pediatr Nephrol 2008; 23: 2201-2207.
68. Voskarides K, Arsali M, Athanasiou Y et al. Evidence that NPHS2-R229Q predisposes to proteinuria and renal failure in familial hematuria. Pediatr Nephrol 2012; 27: 675-679.
69. Kottgen A, Hsu CC, Coresh J et al. The association of podocin R229Q polymorphism with increased albuminuria or reduced estimated GFR in a large population-based sample of US adults. Am J Kidney Dis 2008; 52: 868-875.
70. Pereira AC, Pereira AB, Mota GF et al. NPHS2 R229q functional variant is associated with microalbuminuria in the general population. Kidney Int 2004; 65: 1026-1030.
71. Fakhouri F, Fremeaux-Bacchi V, Noel LH et al. C3 glomerulopathy: a new classification. Nat Rev Nephrol 2010; 6: 494-499.
72. Abrera-Abeleda MA, Nishimura C, Smith JL et al. Variations in the complement regulatory genes factor H (CFH) and factor H related 5 (CFHR5) are associated with membranoproliferative glomerulonephritis type II (dense deposit disease). J Med Genet 2006; 43: 582-589.
73. Monteferrante G, Brioschi S, Caprioli J et al. Genetic analysis of the complement factor H related 5 gene in haemolytic uraemic syndrome. Mol Immunol 2007; 44: 1704-1708.
74. McRae JL, Murphy BE, Eyre HJ et al. Location and structure of the human FHR-5 gene. Genetica 2002; 114: 157-161.
75. Murphy B, Georgiou T, Machet D et al. Factor H-related protein-5: a novel component of human glomerular immune deposits. Am J Kidney Dis 2002; 39: 24-27.
76. Gale DP, de Jorge EG, Cook HT et al. Identification of a mutation in complement factor H-related protein 5 in patients of cypriot origin with glomerulonephritis. Lancet 2010; 376: 794-801.
77. Athanasiou Y, Voskarides K, Gale DP et al. Familial C3 glomerulopathy associated with CFHR5 mutations: clinical characteristics of 91 patients in 16 pedigrees. Clin J Am Soc Nephrol 2011; 6: 1436-1446.
78. Deltas C, Gale D, Cook T et al. C3 glomerulonephritis/CFHR5 nephropathy is an endemic disease in Cyprus: clinical and molecular findings in 21 families. Adv Exp Med Biol 2013; 734: 189-196.
79. Grekas D, Morley AR, Wilkinson R et al. Isolated C3 deposition in patients without systemic disease. Clin Nephrol 1984; 21: 270-274.
80. Servais A, Fremeaux-Bacchi V, Lequintrec M et al. Primary glomerulonephritis with isolated C3 deposits: a new entity which shares common genetic risk factors with haemolytic uraemic syndrome. J Med Genet 2007; 44: 193-199.
81. Vernon KA, Goicoechea de Jorge E, Hall AE et al. Acute presentation and persistent glomerulonephritis following streptococcal infection in a patient with heterozygous complement factor Hrelated protein 5 deficiency. Am J Kidney Dis 2012; 60: 121-125.
82. Malik TH, Lavin PJ, Goicoechea de Jorge E et al. A hybrid CFHR3-1 gene causes familial C3 glomerulopathy. J Am Soc Nephrol 2012; 23: 1155-1160.
83. Martinez-Barricarte R, Heurich M, Valdes-Canedo F et al. Human C3 mutation reveals a mechanism of dense deposit disease pathogenesis and provides insights into complement activation and regulation. J Clin Invest 2010; 120: 3702-3712.
84. Habbig S, Mihatsch MJ, Heinen S et al. C3 deposition glomerulopathy due to a functional factor H defect. Kidney Int 2009; 75: 1230-1234.
85. Flamant M, Bollee G, Henique C et al. Epidermal growth factor: a new therapeutic target in glomerular disease. Nephrol Dial Transplant 2012; 27: 1297-1304.
86. Papagregoriou G, Erguler K, Dweep H et al. A miR-1207-5p binding site polymorphism abolishes regulation of HBEGF and is associated with disease severity in CFHR5 nephropathy. PLoS One 2012; 7: e31021.
87. Barker DF, Pruchno CJ, Jiang X et al. A mutation causing Alport syndrome with tardive hearing loss is common in the western united states. Am J Hum Genet 1996; 58: 1157-1165.
88. Arrondel C, Deschenes G, Le Meur Y et al. A large tandem duplication within the COL4A5 gene is responsible for the high prevalence of Alport syndrome in French polynesia. Kidney Int 2004; 65: 2030-2040.
89. Gould DB, Phalan FC, Breedveld GJ et al. Mutations in Col4a1 cause perinatal cerebral hemorrhage and porencephaly. Science 2005; 308: 1167-1171.
90. Gould DB, Phalan FC, van Mil SE et al. Role of COL4A1 in small-vessel disease and hemorrhagic stroke. N Engl J Med 2006; 354: 1489-1496.
91. Plaisier E, Gribouval O, Alamowitch S et al. COL4A1 Mutations and hereditary angiopathy, nephropathy, aneurysms, and muscle cramps. N Engl J Med 2007; 357: 2687-2695.
92. Mochizuki T, Lemmink HH, Mariyama M et al. Identification of mutations in the alpha 3(IV) and alpha 4(IV) collagen genes in autosomal recessive Alport syndrome. Nat Genet 1994; 8: 77-81.
93. van der Loop FT, Heidet L, Timmer ED et al. Autosomal dominant Alport syndrome caused by a COL4A3 splice site mutation. Kidney Int 2000; 58: 1870-1875.
94. Badenas C, Praga M, Tazon B et al. Mutations in theCOL4A4 and COL4A3 genes cause familial benign hematuria. J Am Soc Nephrol 2002; 13: 1248-1254.
95. Lemmink HH, Nillesen WN, Mochizuki T et al. Benign familial hematuria due to mutation of the type IV collagen alpha4 gene. J Clin Invest 1996; 98: 1114-1118.
96. Barker DF, Hostikka SL, Zhou J et al. Identification of mutations in the COL4A5 collagen gene in Alport syndrome. Science 1990; 248: 1224-1227.
97. Zhou J, Barker DF, Hostikka SL et al. Single base mutation in alpha 5(IV) collagen chain gene converting a conserved cysteine to serine in Alport syndrome. Genomics 1991; 9: 10-18.
98. Zhou J, Mochizuki T, Smeets H et al. Deletion of the paired alpha 5(IV) and alpha 6(IV) collagen genes in inherited smooth muscle tumors. Science 1993; 261: 1167-1169.
99. Seri M, Cusano R, Gangarossa S et al. Mutations in MYH9 result in the May-Hegglin anomaly, and Fechtner and Sebastian syndromes. The May-Heggllin/Fechtner Syndrome Consortium. Nat Genet 2000; 26: 103-105.
100. Seri M, Savino M, Bordo D et al. Epstein syndrome: another renal disorder with mutations in the nonmuscle myosin heavy chain 9 gene. Hum Genet 2002; 110: 182-186.
101. Nester CM, Brophy PD. Eculizumab in the treatment of atypical haemolytic uraemic syndrome and other complement-mediated renal diseases. Curr Opin Pediatr 2013; 25: 225-231.
102. Friedman David J, Pollak Martin R. Genetics of kidney failure and the evolving story of APOL1. J Clin Invest 2011; 121: 3367-3374.
103. Geiss-Liebisch S, Rooijakkers SH, Beczala A, Sanchez-Carballo P, Kruszynska K, Repp C, Sakinc T, Vinogradov E, Holst O, Huebner J, Theilacker C. Secondary cell wall polymers of Enterococcus faecalis are critical for resistance to complement activation via mannose-binding lectin. J Biol Chem 2012; 287: 37769-37777.
104. Pezzolesi MG, Krolewski AS. The genetic risk of kidney disease in type 2 diabetes. Med Clin North Am 2013; 97: 91-107.